# Safety and Efficacy of "Immuncell-LC" in TACE Therapy

> **NCT02856815** · PHASE2 · COMPLETED · sponsor: **GC Cell Corporation** · enrollment: 76 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **BIOLOGICAL:** Immuncell-LC

## Key facts

- **NCT ID:** NCT02856815
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-28
- **Primary completion:** 2020-08-11
- **Final completion:** 2022-09-22
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856815, "Safety and Efficacy of "Immuncell-LC" in TACE Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02856815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*